Similarly, Matthias Friedrich et al. also showed that blocking IL-1 may be useful in patients with deep ulcers who have failed to respond to conventional therapies, and hence could potentially improve the outcome of patients with IBD (42). The gene discussed is IL1A; the disease is inflammatory bowel disease.